Liu SY, Ahsan Bilal M, Zhu JH, Li SM. Diagnostic value of serum human epididymis protein 4 in esophageal squamous cell carcinoma. World J Gastrointest Oncol 2020; 12(10): 1167-1176 [PMID: 33133384 DOI: 10.4251/wjgo.v12.i10.1167]
Corresponding Author of This Article
Shi-Yuan Liu, MD, PhD, Associate Professor, Department of Thoracic Surgery, Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwu Road, Xi'an 710004, Shaanxi Province, China. twinboysdoctors@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Oct 15, 2020; 12(10): 1167-1176 Published online Oct 15, 2020. doi: 10.4251/wjgo.v12.i10.1167
Diagnostic value of serum human epididymis protein 4 in esophageal squamous cell carcinoma
Shi-Yuan Liu, Muhammad Ahsan Bilal, Jian-Hong Zhu, Shao-Min Li
Shi-Yuan Liu, Shao-Min Li, Department of Thoracic Surgery, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi Province, China
Muhammad Ahsan Bilal, Department of Dermatology and Venereology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi Province, China
Jian-Hong Zhu, Department of Clinical Laboratory, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi Province, China
Author contributions: Liu SY and Li SM designed the research; Zhu JH, Liu SY, and Bilal MA performed the research; Liu SY and Zhu JH analyzed the data; Liu SY and Bilal MA wrote the paper.
Supported byNational Natural Science Foundation of China, No. 81602023.
Institutional review board statement: The study procedures were approved by the ethical committee of the Second Affiliated Hospital of Xi'an Jiaotong University.
Informed consent statement: Patients were not required to give any informed consent to this study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment, and operative pathological examination by written consent. Individuals can’t be identified according to the data presented.
Conflict-of-interest statement: None.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Shi-Yuan Liu, MD, PhD, Associate Professor, Department of Thoracic Surgery, Second Affiliated Hospital of Xi'an Jiaotong University, No. 157 Xiwu Road, Xi'an 710004, Shaanxi Province, China. twinboysdoctors@163.com
Received: April 13, 2020 Peer-review started: April 13, 2020 First decision: April 26, 2020 Revised: May 24, 2020 Accepted: August 25, 2020 Article in press: August 25, 2020 Published online: October 15, 2020 Processing time: 184 Days and 3.8 Hours
Core Tip
Core Tip: Numerous studies have demonstrated that human epididymis protein 4 (HE4) is overexpressed in various malignant tissues including ovarian, endometrial, lung, breast, pancreatic, and gastric cancers. However, no study has examined the diagnostic impact of HE4 in patient with esophageal squamous cell carcinoma (ESCC) until now. In this study, we quantified serum HE4 levels via ELISA using a non-biased database consisting of 80 ESCC patients, which were compared to a control group of 56 patients with benign esophageal disease. It was found that serum HE4 was significantly higher in ESCC patients than in the control group, and the staining intensity was inversely correlated with the pathological T and N stages. It has been suggested that serum HE4 can have a potential role as an early diagnostic biomarker for ESCC.